Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A, ERIVANCE BCC Investigators. · 2017

Read Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. by Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A, ERIVANCE BCC Investigators. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5433030.txt.

Description

Sekulic and co-authors report the final long-term results of vismodegib for advanced basal cell carcinoma. Their trial update appeared in BMC Cancer. Basal cell carcinoma is the most common human cancer. Most cases yield to surgery or radiation. Faulty Hedgehog signaling drives most of these tumors. Vismodegib blocks that pathway. The ERIVANCE trial enrolled 104 patients.

Patients took 150 milligrams once daily. Treatment ran until progression or harsh side effects. At cutoff, 39 months after accrual closed, eight patients remained on drug. Investigator-assessed response reached about 49 percent in metastatic disease. All those responses were partial. Locally advanced disease responded at just over 60 percent. Twenty patients there had complete responses. Median response lasted about 15 months in one group and 26 months in the other. Median survival in metastatic disease was about 33 months. Thirty-three deaths occurred, none blamed on the drug.

Catalog record

CREATORSekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A, ERIVANCE BCC Investigators.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5433030

Browse the full library · About the Tower of Babel